demonstrated that nuclear PIP5K1A stabilizes stress‐induced wild‐type and mutant p53, suggesting a potential therapeutic target for cancers with mutant p53.[23] According to TCGA database, ≈16% of HCC cases harbor PIP5K1A mutations, implicating its potential oncogenic role in HCC. The gene discussed is TP53; the disease is cancer.